Navigation Links
Positive Phase III Top Line Results Demonstrate Efficacy of NER1006, a Novel, Low Volume Bowel Preparation, vs. Trisulfate
Date:10/8/2015

LONDON, October 9, 2015 /PRNewswire/ --

Norgine today announced positive top line results for its phase III study, NOCT, a multicentre, randomised, parallel-group clinical trial comparing the bowel cleansing efficacy of a two-day split-dosing regimen of NER1006, versus a split-dosing regimen of a trisulfate bowel cleansing solution (SUPREP®) in adult patients undergoing screening, surveillance or diagnostic colonoscopy. The NOCT study also assessed the compliance, safety, patient acceptability and tolerability of NER1006.

     (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a)

The NOCT study, which enrolled 621 patients, met both of its primary endpoints.

Peter Martin, Norgine's Chief Operating Officer, said; "These positive top-line results demonstrate the potential of NER1006 as a novel bowel cleansing agent to deliver an effective colonoscopy. These data are encouraging as a major milestone on the development of this novel bowel cleansing agent".

The NOCT study is part of Norgine's NER1006 Phase III clinical trials programme. The programme includes two additional multicentre, randomised, parallel-group clinical trials, MORA and DAYB, that are expected to report in 2015.

Full evaluation of the data is ongoing. Complete results from the NOCT study will be submitted to a scientific meeting in 2016. NER1006 is not approved for use.

Notes to Editors: 

About NER1006 

NER1006 is a novel, low volume polyethylene glycol based bowel preparation that has been developed to provide whole bowel cleansing, with an additional focus on the ascending colon. This low volume solution is developed not only to support improved patient acceptability and compliance but also to contribute to effectiveness of colonoscopy procedures at detecting colon cancer and for optimised bowel surveillance, through effective bowel cleansing.

About Norgine 

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2014, Norgine's total revenue was €296 million and the company employs over 1,000 people.

Norgine provides expertise and 'know how' in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine's approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales, and one in Dreux, France.

For more information, please visit http://www.norgine.com

In 2012, Norgine established a complementary business, Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit http://www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

GL/COR/1015/0049. October 2015

Media Contacts:
Isabelle Jouin, T: +44(0)1895-453643
Charlotte Andrews, T: +44(0)1895-453607
Follow us @norgine


'/>"/>
SOURCE Norgine B.V.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. SynAgile Corporation Announces Positive Phase 2a Results for Continuous, Noninvasive, Intraoral Levodopa-Carbidopa Administration to Treat Parkinsons Disease
2. Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
3. QT Vascular Announces Positive Outcome in Spectranetics/AngioScore Patent Trial
4. Regen BioPharma, Inc. Announces Positive Results from GLP Safety Study for HemaXellerate
5. Amgen Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe
6. Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide
7. Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study
8. BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ
9. Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial
10. Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome
11. Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2018)... DALLAS (PRWEB) , ... August 15, 2018 , ... Help ... helps Type 2 Diabetics reverse their disease and get off their medication, working in ... 27 years of experience in healthcare and is the author of "Imagine Living Without ...
(Date:8/14/2018)... ... August 14, 2018 , ... Children’s National Health System and ... to expand a popular pet therapy program. , The grant will enable ... visits to patients throughout the hospital and outpatient clinics. With this critical funding ...
(Date:8/11/2018)... ... August 11, 2018 , ... Lefty’s ... 13, with fun, games and gifts. Left-Handers are possibly the world’s largest silent ... Having endured centuries of prejudice, countless indignities and inconveniences, left-handers quietly learn to ...
Breaking Medicine Technology:
(Date:8/11/2018)... ... August 10, 2018 , ... TopConsumerReviews.com recently ... , What is gout? This painful, persistent condition originates in the liver and ... levels of uric acid. Other contributing factors may be medication side effects, overweight, ...
(Date:8/9/2018)... ... August 09, 2018 , ... Lyme disease is one of the ... to an estimated 329,000 – a 25-fold increase since surveillance began in 1982. According ... be found all 50 states and the District of Columbia. Yet, Lyme and other ...
(Date:8/7/2018)... ... August 07, 2018 , ... Josh Sprague, Founder and CEO of athletic goods ... the upcoming Leadville 100 MTB. , Accompanied by colleague Marvin Sandoval and equipped ... called “one of the most iconic mountain bike race courses in the world.” ...
(Date:8/3/2018)... ... , ... On August 2, 2018 the JPML ordered that the Zostavax MDL ... LLC has been litigating Zostavax injuries since 2011. , ... for the thousands of people injured by Zostavax, a vaccine given to adults to ...
(Date:8/2/2018)... ... August 02, 2018 , ... Mindray, a developer of next ... unique new upgrades at the Society of Vascular Ultrasound annual conference being held ... the upgrades include a unique arterial stiffness measurement, which uses radiofrequency data-based quantitative ...
Breaking Medicine News(10 mins):